Manganese compound and preparation method and application thereof

Abstract

The invention discloses a manganese compound and a preparation method and application thereof, and relates to the technical field of magnetic resonance imaging (MRI). The manganese compound is dichloro-N-(2-propionic carbethoxy)-N,N-bis(2-picolyl) amine synthetic manganese, and the molecular formula is C17H21Cl2MnN3O2. The preparation method for the manganese compound comprises the following steps: dissolving ligand dichloro-N-(2-propionic carbethoxy)-N,N-bis(2-picolyl) amine and MnCl2 into aqueous solution in a molar ratio of 1 to 1, and controlling the temperature to be between 20 and 40 DEG C; and synthesizing ammonium chloride and a catalyst in a molar ratio of the ammonium chloride to the MnCl2 of 0.2 to 1, reacting the mixture at the temperature of 30 DEG C for 1 to 4 hours, purifying a product by using silica gel column chromatography, concentrating the product and removing the solution to obtain light yellow manganese compound. The manganese compound is applied in the aspect of magnetic resonance imaging in a liver cancer body; and compared with the blank aqueous solution without the manganese compound, the compound can remarkably improve the tumor diagnosis effect, has magnetic resonance imaging function and tumor targeting property, and can be used as a magnetic resonance imaging contrast agent for the tumor.

Description

technical field The invention relates to the technical field of magnetic resonance imaging (MRI), in particular to an imaging agent for magnetic resonance imaging and an application thereof. Background technique Magnetic resonance imaging (MRI) is a noninvasive and rapid imaging method for the detection of brain tumors and blood vessels. Magnetic resonance imaging has the advantages of safety, non-invasiveness, no ionizing radiation, no radiation damage, high time resolution and spatial resolution, and has become the main imaging technology for clinical diagnosis of vascular lesions and intracranial tumors. Since Gd-DTPA was used in clinical trials in 1983, in order to improve the sensitivity and targeting of imaging agents and reduce their toxicity, people have carried out a lot of research and development on MRI contrast agents (B.Jebasingh, V.Alexander.Inorg.Chem. , 2005, 44:9434-9443). Commonly used imaging agents are gadolinium diethylenetriaminepentaacetate (Gd-DTPA)...

AI Technical Summary

Problems solved by technology

Magnetic resonance imaging contrast agent with tumor therapeutic effect has not been reported

Images